Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Elanco licenses canine pain drug
by Ann M. Thayer
May 2, 2016
| A version of this story appeared in
Volume 94, Issue 18
Eli Lilly & Co.’s Elanco animal health division has licensed rights to a canine pain drug developed by Kansas-based Aratana Therapeutics. Approved by FDA in March, Galliprant is a noncyclooxygenase-inhibiting, nonsteroidal anti-inflammatory designed to control osteoarthritic pain and inflammation in dogs. Elanco is paying $45 million up front and up to $83 million in milestones. Aratana licensed the drug for animal use in 2011 from Japan’s RaQualia Pharma. Aratana says it should be available in the fall.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter